Detalles de la búsqueda
1.
Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Cancer
; 129(24): 3873-3883, 2023 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37538036
2.
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
BMC Med
; 21(1): 72, 2023 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36829154
3.
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
BMC Cancer
; 23(1): 206, 2023 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36870951
4.
Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner.
Future Oncol
; 19(33): 2251-2261, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37909261
5.
Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.
BMC Med
; 20(1): 12, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35039026
6.
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
BMC Med
; 20(1): 277, 2022 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36031613
7.
Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
J Transl Med
; 20(1): 248, 2022 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35642002
8.
A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
Oncologist
; 25(5): e833-e842, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32250517
9.
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
J Cell Mol Med
; 23(10): 6812-6821, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31393074
10.
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Invest New Drugs
; 37(4): 731-737, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706337
11.
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment.
Chin J Cancer Res
; 31(2): 349-356, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31156305
12.
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.
Chin J Cancer Res
; 31(3): 481-488, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31354217
13.
Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.
Chin J Cancer Res
; 29(1): 18-24, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28373750
14.
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
BMC Cancer
; 16: 265, 2016 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27061082
15.
Efficacy of third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in advanced NSCLC with different T790M statuses tested via digital droplet polymerase chain reaction ddPCR and next-generation sequencing.
Expert Rev Anticancer Ther
; 24(3-4): 183-192, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526910
16.
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Lung Cancer
; 189: 107503, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38359741
17.
Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.
Chin J Cancer Res
; 25(2): 200-5, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23592901
18.
Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.
Ther Adv Med Oncol
; 15: 17588359231179315, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37389188
19.
Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.
Cancer Innov
; 2(1): 65-78, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38090369
20.
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Cancer Med
; 12(1): 335-344, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608132